These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2577457)

  • 1. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1763-6. PubMed ID: 2904747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of doxazosin versus atenolol in mild-to-moderate hypertension.
    Giorgi G; Legramante JM; Fioravanti G; Paies G; Legramante A
    Am Heart J; 1988 Dec; 116(6 Pt 2):1801-5. PubMed ID: 2904754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
    Trost BN; Weidmann P; Riesen W; Claessens J; Streulens Y; Nelemans F
    Am J Cardiol; 1987 May; 59(14):99G-104G. PubMed ID: 2884861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic stature of doxazosin and its role in coronary risk reduction.
    Taylor SH
    Am Heart J; 1988 Dec; 116(6 Pt 2):1735-47. PubMed ID: 2904744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardiovascular effects of alpha-receptor blocking agents.
    Leren P
    J Hypertens Suppl; 1992 Jun; 10(3):S11-4; discussion S14-5. PubMed ID: 1353110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with doxazosin in general medical practice.
    Rosenthal J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1748-57. PubMed ID: 2904745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of alpha-blockers in the management of hypertension: a practical view.
    McInnes GT
    J Hum Hypertens; 1991 Aug; 5(4):313-6. PubMed ID: 1683406
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    Talseth T; Westlie L; Daae L; Vatle S
    Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma.
    Miura Y; Yoshinaga K
    Am Heart J; 1988 Dec; 116(6 Pt 2):1785-9. PubMed ID: 2904751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
    Hayduk K; Schneider HT
    Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
    Pool JL
    Am Heart J; 1991 Sep; 122(3 Pt 2):926-31. PubMed ID: 1678924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy.
    Englert RG; Mauersberger H
    Am Heart J; 1988 Dec; 116(6 Pt 2):1826-32. PubMed ID: 2904758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-blind study of doxazosin in the treatment of mild-to-moderate essential hypertensive patients with concomitant noninsulin-dependent diabetes mellitus.
    Castrignano R; D'Angelo A; Pati T; Al Awady M; Tronca R; Crepaldi G
    Am Heart J; 1988 Dec; 116(6 Pt 2):1778-84. PubMed ID: 2904750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparative study of doxazosin and nitrendipine in patients with mild-to-moderate essential hypertension.
    Nechwatal W; Berger J; Blumrich W; Bouzo H; Brandl K; Braun S; Laukaitis A; Müller G; Ryba W; Schreiegg J
    Am Heart J; 1988 Dec; 116(6 Pt 2):1806-14. PubMed ID: 2904755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension.
    Taylor SH; Lee PS; Sharma SK
    Am Heart J; 1988 Dec; 116(6 Pt 2):1820-5. PubMed ID: 2904757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.